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New insights into the heterogeneity 
of Th17 subsets contributing to HIV-1 
persistence during antiretroviral therapy
Vanessa Sue Wacleche1,2, Jean‑Philippe Goulet3, Annie Gosselin2, Patricia Monteiro1,2, Hugo Soudeyns1,4, 
Rémi Fromentin2, Mohammad‑Ali Jenabian5, Shant Vartanian6, Steven G. Deeks6, Nicolas Chomont1,2, 
Jean‑Pierre Routy7,8 and Petronela Ancuta1,2*
Abstract 
Background: Th17 cells are permissive to HIV‑1 infection and their depletion from the gut of infected individu‑
als leads to microbial translocation, a major cause for non‑AIDS co‑morbidities. Most recent evidence supports the 
contribution of long‑lived Th17 cells to HIV persistence during antiretroviral therapy (ART). However, the identity of 
long‑lived Th17 cells remains unknown.
Results: Here, we performed an in‑depth transcriptional and functional characterization of four distinct Th17 subsets 
and investigated their contribution to HIV reservoir persistence during ART. In addition to the previously character‑
ized CCR6+CCR4+ (Th17) and CCR6+CXCR3+ (Th1Th17) subsets, we reveal the existence of two novel CCR6+ subsets, 
lacking (double negative, CCR6+DN) or co‑expressing CXCR3 and CCR4 (double positive, CCR6+DP). The four subsets 
shared multiple Th17‑polarization markers, a fraction of cells proliferated in response to C. albicans, and exhibited 
lineage commitment and plasticity when cultured under Th17 and Th1 conditions, respectively. Of note, fractions of 
CCR6+DN and Th17 demonstrated stable Th17‑lineage commitment under Th1‑polarization conditions. Among the 
four subsets, CCR6+DN expressed a unique transcriptional signature indicative of early Th17 development (IL‑17F, 
STAT3), lymph‑node homing (CCR7, CD62L), follicular help (CXCR5, BCL6, ASCL2), and self‑renewal (LEFI, MYC, TERC). 
Cross sectional and longitudinal studies demonstrated that CCR6+DN cells were the most predominant CCR6+ subset 
in the blood before and after ART initiation; high frequencies of these cells were similarly observed in inguinal lymph 
nodes of individuals receiving long‑term ART. Importantly, replication competent HIV was isolated from CCR6+DN of 
ART‑treated individuals.
Conclusions: Together, these results provide new insights into the functional heterogeneity of Th17‑polarized 
CCR6+CD4+ T‑cells and support the major contribution of CCR6+DN cells to HIV persistence during ART.
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Background
The Th17 cells represent a subset of CD4+ T-cells that 
act as the first line of defense against pathogens at barrier 
surfaces [1]. Th17 cells are defined by the production of 
unique effector cytokines (IL-17A, IL-17F, IL-21, IL-22, 
IL-26, CCL20) under the transcriptional regulation of 
multiple lineage-specific transcription factors (IRF4, 
BATF, STAT3, RORγt) [2, 3]. Their anatomic localization 
and effector functions, together with their unique devel-
opmental plasticity, position Th17 cells at the very core 
of the immune system [2, 4]. CCR6 is a well-established 
marker for Th17 cells [5, 6]. CCR6 mediates recruitment 
into specific tissues including Peyer’s patches (CCR6 [7]), 
skin [8] and brain [9]. Although not all CCR6+ T-cells 
produce IL-17A upon stimulation ex vivo, the majority of 
these cells are prone to acquire Th17 effector functions 
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[10]. The co-expression of CCR6 and CCR4 identifies 
cells producing IL-17A (Th17 profile) specific to Can-
dida albicans and Staphylococcus aureus [5, 11], while 
CCR6+CXCR3+ cells produce both IL-17A and IFN-γ 
(Th1Th17 profile) in response to Mycobacterium tuber-
culosis or upon polyclonal stimulation [ [5], [12] ]. These 
advances in the identification of surface markers for 
functionally distinct CD4+ T cell subsets proved to be 
instrumental for understanding the contribution of Th17 
cells to human pathologies including rheumatoid arthri-
tis [13], multiple sclerosis [9], cancer [14], and HIV-infec-
tion [15, 16].
The existence of functionally distinct IL-17A-producing 
CD4+ T-cells cells was originally reported in the context 
of autoimmunity, with CCR6+CXCR3+Th1Th17 and 
CCR6+CCR4+Th17 cells being considered pathogenic and 
non-pathogenic, respectively [3, 17]. This discovery led to 
the identification of molecular signatures associated with 
Th17 pathogenicity in mice [18–20] and most recently 
in humans [21]. In contrast, during HIV-1 infection, we 
previously demonstrated that both CCR6+CCR4+Th17 
and CCR6+CXCR3+Th1Th17 cells are pathogenic since 
they are permissive to viral infection in vitro, carry inte-
grated HIV-DNA in  vivo, and their frequency is signifi-
cantly reduced in HIV-infected individuals, including 
those with undetectable plasma viral load under antiret-
roviral therapy (ART) [15]. Considering the fact that IL-
17A plays a critical role in maintaining epithelial barrier 
integrity at intestinal level [22, 23], the depletion of Th17 
and Th1Th17 cells from gut-associated lymphoid tis-
sues (GALT) is considered as a major cause for microbial 
translocation, chronic immune activation and occurrence 
of non-AIDS co-morbidities in HIV-infected individu-
als [24]. Thus, features of Th17 pathogenicity are unique 
in the context of HIV infection. In addition, long-lived 
Th17 cells exist and were reported to promote cancer pro-
gression [25]. The possibility that long-lived Th17 cells 
contribute to HIV reservoir persistence under ART, as 
supported by recent findings by our group (Gosselin et al, 
unpublished observations) and others [26], adds to the 
complexity of Th17 pathogenicity concept and position 
these cells as a major barrier for HIV eradication.
In this study, we used a systems biology approach an 
revealed phenotypic, functional and transcriptional fea-
tures of two previously uncharacterized human CD4+ 
T-cell subsets expressing the Th17 marker CCR6 and 
lacking or co-expressing the homing receptors CCR4 and 
CXCR3: CCR4−CXCR3− (double negative; CCR6+DN) 
and CCR4+CXCR3+ (double positive; CCR6+DP). Our 
results provide new insights into the diversity of Th17 sub-
sets during homeostasis and HIV-1 infection, thus adding 
a novel piece of complexity to the recent understanding 
of Th17 functional heterogeneity and clonotype sharing in 
humans [27]. We reveal that CCR6+DN are distinguished 
from Th17, Th1Th17 and CCR6+DP by their expression of 
markers of early Th17 development, lymph node traffick-
ing, follicular help and self-renewal. We also demonstrate 
that CCR6+DN represent the most predominant Th17 
subset in the blood and lymph nodes of HIV-infected 
ART-treated individuals and carry replication-competent 
integrated HIV-DNA. These findings support the newly 
emerged concept that HIV takes advantage of the long-
lived properties of specific Th17 subsets [25, 28, 29] to 
ensure its persistence during ART. Thus, permissiveness 
to HIV-DNA integration compatible with survival rep-
resents a new previously unrecognized feature of patho-
genic Th17 cells during HIV infection
Results
Two novel subsets of memory CCR6+ T‑cells exhibit 
Th17‑features
Differential expression of CCR4 and CXCR3 identifies 
four memory (CD45RA−) CCR6+ and four CCR6− sub-
sets. The following four subsets were previously demon-
strated to be enriched in cells with specific polarization 
features: CCR6+CCR4+ (Th17) and CCR6+CXCR3+ 
(Th1Th17), CCR6−CXCR3+ (Th1), and CCR6−CCR4+ 
(Th2) [5, 15, 27]. While acknowledging the fact that these 
subsets are heterogeneous, for simplicity, these subsets 
are typically identified as Th17, Th1Th17 (or Th1*), Th1, 
or Th2 cells [5, 12, 21, 27]. We previously demonstrated 
that Th17 and Th1Th17 subsets are highly permissive to 
R5 and X4 HIV-1 infection in vitro [15]. Among CCR6+ 
T-cells, two subsets remain uncharacterized in terms of 
polarization profile and contribution to HIV-1 patho-
genesis: CCR4−CXCR3− (double negative; CCR6+DN) 
and CCR4+CXCR3+ (double positive; CCR6+DP) 
(Fig.  1a). In HIV-uninfected individuals, the frequency 
of blood CCR6+DN was similar to that of Th17 and 
Th1Th17, while the frequency of CCR6+DP was slightly 
lower (Fig.  1b). The CCR6− population also included 
two previously uncharacterized subsets, CCR6−DN and 
CCR6−DP, with CCR6−DN being the most predomi-
nant (Fig.  1a, b). CCR6+DN and CCR6+DP expressed 
the Th17 marker CD161 [30] at levels higher and similar 
compared to Th17 and Th1Th17, respectively (Fig.  1c). 
The frequency of cells expressing CD161 was relatively 
low on CCR6− subsets (Fig. 1c). CCR7 and CD27 iden-
tify distinct memory subsets [31, 32]: CCR7+CD27+ 
(CM, central memory), CCR7−CD27− (EM, effector 
memory), CCR7−CD27+ (TM, transitional memory) and 
CCR7+CD27− subset. CM predominated over EM and 
TM in all CCR6+ subsets, with the highest % of CM in 
Th1Th17 and CCR6+DP (Fig. 1d).
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For subsequent functional studies, sufficient numbers 
of highly pure CCR6+ and CCR6− cells with differen-
tial CCR4 and CXCR3 expression were sorted by flow 
cytometry from large numbers of PBMCs (109) obtained 
by leukapheresis (Additional file 1: S1 Figure) from HIV-
uninfected individuals. To determine the polarization 
profile of CCR6+DN and CCR6+DP, the expression of 
lineage-specific cytokines was measured in FACS-sorted 
cells exposed to CD3/CD28 triggering. Compared to 
Th17 and Th1Th17, CCR6+DN and CCR6+DP produced 
high and low levels of IL-17A, respectively. In contrast 
to Th17, CCR6+DN and CCR6+DP produced IFN-γ but 
at significantly lower levels compared to Th1Th17; as 
expected, the Th2 cytokine IL-5 was produced by CCR6− 
but not CCR6+ cells (Fig. 1e).
To further investigate the Th17 polarization pro-
file of CCR6+DN and CCR6+DP, their transcriptome 
was compared to that of Th17 and CCR6−DN using the 
Illumina technology. The list of 1020 transcripts dif-
ferentially expressed in CCR6+DN versus CCR6−DN 
(adjusted p value >0.05; FC cut-off 1.3), included well-
established markers for Th17 (IL-17F, KLRB1/CD161, 
CCL20, KLF2, CTSH, IL-22, CCR6, RORA, IL-23R, 
RORC, PTPN13, IL-26, S100A4, ARNTL, IL-6R) and 
Th1 lineages (CCL3L3, CCL3, CCL3L1, CCL5, CD300a), 
potentially new Th17 markers (CD96, LGMN, ANTXR2, 
CXCR6, MAP3K4, TNFSF25, LY9, S1PR1), together 
with negative regulators of Th17 polarization (IL-9, 
IFITM3, OSM, IRF8, MX1, NFIL3, PTK2, IL4R, SOCS1) 
(Fig. 1f ). Clustering analysis of these transcripts grouped 
all CCR6+ subsets together, indicative of their common 
Th17 polarization. These results identify CCR6+DN and 
CCR6+DP as two novel Th17 subsets, with CCR6+DN 
producing high levels of IL-17A and being as preponder-
ant as the previously described Th17 and Th1Th17 in the 
peripheral blood of healthy humans [5].
Th17‑polarized CCR6+DN and CCR6+DP subsets exhibit 
unique transcriptional profiles
Further analysis of transcriptional profiles identified 
344, 1407 and 3148 probe-sets differentially expressed 
by CCR6+DN versus Th17, CCR6+DP versus Th17, and 
CCR6+DN versus CCR6+DP (p-value <0.05; FC cut-off 
1.3), respectively (Fig. 2a). Differences in gene expression 
in CCR6+DN versus Th17 (13 up; 13 down) were also 
found inferior to differences in CCR6+DP versus Th17 
(368 up; 357 down) and CCR6+DN versus CCR6+DP 
(1537 up; 1417 down), when transcripts with adjusted 
p-values  <0.05 were considered (Additional file  2: Table 
S1, data not shown). These results reveal the transcrip-
tome of CCR6+DN is similar to that of Th17, but highly 
distinct from that of CCR6+DP. Of note, IL-17F, a 
cytokine associated with early Th17 development [33], 
was included among the top up-regulated transcripts in 
CCR6+DN versus Th17 (FC: 7.8) and CCR6+DN versus 
CCR6+DP (FC: 12.8) (Additional file 2: Table S1). In con-
trast, LMNA, a senescence marker [34], was included 
among the top down-regulated genes in CCR6+DN ver-
sus Th17 (FC: −2.2) and CCR6+DN versus CCR6+DP 
(FC: −4).
To extract functional meaning from these transcrip-
tional dissimilarities, Ingenuity Pathway Analysis (IPA), 
(See figure on next page.) 
Fig. 2 CCR6+DN and CCR6+DP cells express unique transcriptional signatures. Genome‑wide transcriptional profiling was performed on sorted 
matched Th17, CCR6+DN, and CCR6+DP (n = 4–6) isolated from the peripheral blood of HIV‑uninfected individuals, as in Fig. 1f. Shown are (a) 
volcano representation of differentially expressed probe sets in CCR6+DN versus Th17, CCR6+DP versus Th17, and CCR6+DN versus CCR6+DP 
(depicted in red: p values <0.05 and fold change cut‑off 1.3). b, d For the same contrasts, shown are heat maps depicting top modulated pathways 
identified using Ingenuity Pathway Analysis (IPA) (b) and Gene Set Variation Analysis (GSVA) canonical pathways (c) and biological functions (d). Genes 
up and down regulated in different subsets are represented in red and blue, respectively. e Expression of STAT3, BCL6, LEF1, and TERC mRNA was 
quantified by real‑time RT‑PCR (mean ± SEM; n = 3–4). Paired t‑Test p‑values are indicated on the figures
(See figure on previous page.) 
Fig. 1 Two new subsets of memory CD4+ T‑cells express Th17 lineage markers. a Memory CD4+ T‑cells (CD3+CD4+CD45RA−) isolated from the 
peripheral blood of HIV‑uninfected individuals were analyzed for their differential expression of CCR6, CCR4, and CXCR3. CCR6+ subsets included: 
CCR4+CXCR3− (Th17), CCR4−CXCR3− (double positive, CCR6+DP), CCR4+CXCR3+ (double negative, CCR6+DN), and CCR4−CXCR3+ (Th1Th17). 
CCR6− subsets included: CCR4+CXCR3− (Th2), CCR4+CXCR3+ (CCR6−DP), CCR4−CXCR3− (CCR6−DN) and CCR4−CXCR3+ (Th1). Shown is the 
frequency of CCR6+ and CCR6− subsets (b; n = 30) and their expression of CD161 (c; n = 8). Each symbol represents a distinct subject. Paired t‑Test 
p‑values are indicated on the figures. Horizontal bars indicate median values. d Shown are median frequencies of central (CM, CCR7+CD27+), tran‑
sitional (TM, CCR7−CD27+) and effector (EM, CCR7−CD27−) memory cells per CCR6+ subset (n = 10). e–g FACS‑sorted memory subsets (S1 Figure) 
were stimulated via CD3/CD28 for 4 days. e The production of the lineage‑specific cytokines IL‑17A, IFN‑γ, and IL‑5 was quantified by ELISA. Shown 
are results (mean ± SEM) on matched Th17, Th1Th17, CCR6+DN, CCR6+DP, and CCR6‑ (n = 3–7). Paired t Test p‑values are indicated on the figures.  
f Transcriptional profiling were generated using the HumanHT‑12 v4 Expression BeadChip; (Illumina). The heat map depicts differential expression 
of well‑established Th17 and Th1 transcripts (identified as being up/down regulated in Th17 versus CCR6−DN, p value <0.05, fold change cut‑off 1.3) 
in matched CCR6−DN versusCCR6+DN, CCR6+DP and Th17 (n = 4–6; up‑regulated genes in red; down‑regulated genes in blue)
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Gene Set Variation Analysis (GSVA), and Gene Ontol-
ogy (GO) tools were used to identify differentially 
expressed pathways and biological functions. IPA iden-
tified the most significant differences for the CCR6+DN 
versus CCR6+DP and Th17 versus CCR6+DP contrasts, 
and revealed similarities between CCR6+DN and Th17 
(Fig.  2b). Among top modulated pathways, PPAR/RXR 
(previously associated with the negative regulation of 
Th17 polarization [35]), cyclin and cell cycle regula-
tion, and apoptosis pathways were under represented 
in CCR6+DN versus CCR6+DP. In contrast, IL-6, phos-
pholipase C (both involved in Th17 differentiation [29] 
CXCR4, thrombin, p38/ERK/MAPK (involved in cell 
activation/proliferation [36]) and Tec Kinase (involved 
in TCR signaling [37]) were over expressed in CCR6+DN 
versus CCR6+DP and in CCR6+DN versus Th17. Other 
pathways specifically up-regulated in CCR6+DN versus 
CCR6+DP and Th17 versus CCR6+DP included IL-2, 
Jak/STAT, PKC, sphingosine-1-phosphate (involved in 
cell migration [38]), NANOG (implicated in the mainte-
nance of stem cells [39]), IL-3 (involved in lymphopoiesis 
[40]), PI3 K (involved in Th17 differentiation [10], April 
(involved in Th17 polarization [41], and NFAT (involved 
in IL-17A production [42]) (Fig. 2b).
GSVA identified canonical pathways (C2) and biologi-
cal processes (C5) differentially expressed in CCR6+DN 
versus CCR6+DP and Th17 versus CCR6+DP (Addi-
tional file 3: S2A-B Figure). Among the top 50 differen-
tially-expressed canonical pathways, the IL-23 pathway, 
which is key for Th17 polarization [43], was found to be 
enriched in CCR6+DN (Fig. 2c). Among the top 50 dif-
ferentially-expressed biological processes, the expression 
of pathways such as lymphocyte differentiation, protease 
inhibitor and response to steroid hormone receptor were 
over represented in CCR6+DN (Fig. 2d).
GO identified differentially-expressed genes in 
CCR6+DN versus CCR6+DP (p  <  0.05, cut-off 1.3-fold) 
involved in cell migration, chemotaxis, cell differen-
tiation, and transcription. Transcripts associated with 
migration/chemotaxis into/outside lymph nodes, includ-
ing CCR7, CXCR5, the CXCR5 ligand CXCL13, SELL, 
SIRP1, JAM3 and AIF1 were enriched in CCR6+DN, 
whereas adhesion molecules/chemokine receptors 
mediating homing into peripheral tissues such as inte-
grin β7 (gut), CXCR3 (inflammatory sites), CCR2 and 
CCR4 (skin), and integrin β1 (cervix) were enriched in 
both Th17 and/or CCR6+DP (Additional file  3: S2C-D 
Figure). Well-established markers of Th17 (IL-8, IL-23R, 
SOSC3, TIM3, CD26/DPP4) and follicular helper T 
cells (Tfh) (CXCR5, ICOS) were enriched in CCR6+DN 
(Additional file  3: S2E Figure). Also, transcription fac-
tors related to the control of Th17 (STAT3, RORA) and 
Tfh (BLC6, ASCL2 [44, 45]) polarization/function were 
enriched in CCR6+DN (Additional file 3: S2E-F Figure). 
In addition, other transcripts enriched in CCR6+DN ver-
sus CCR6+DP include LEF1 and MYC, key markers of 
human stem-cells and long-lived Th17 cells [25], together 
with the anti-senescence marker TERC [46] (Additional 
file 2: Table S1). RT-PCR quantifications confirmed supe-
rior expression of STAT3, BCL6, LEF1 and TERC in 
CCR6+DN versus Th17 and CCR6+DP (Fig.  2e). These 
transcriptional analyses suggest that CCR6+DN, Th17 
and CCR6+DP represent distinct stages of Th17 differ-
entiation with specific migration potential, immuno-
logical functions, and transcriptional regulation. Among 
these subsets, CCR6+DN exhibit markers of early Th17 
commitment, lymph-node tropism, follicular help, and 
self-renewal.
CCR6+DN are a major source of IL‑17F, IL‑8 and IL‑21
A Cytokine Array was used to screen for the presence of 
34 lineage-specific cytokines produced by CD3/CD28-
activated CCR6+ subsets of HIV-uninfected individuals. 
CCR6+DN were distinguished from Th17 by increased 
IFN-γ, IL-17A, IL-17F, MIP-3α/CCL20 and TNF-α 
and decreased IL-13 (Fig.  3a), and from Th1Th17, by 
increased IL-17A and IL-17F, and decreased IFN-γ and 
TNF-α production (Fig.  3b). Levels of GM-CSF, IL-10 
and IL-22 were similarly high in CCR6+DN, Th17 and 
Th1Th17 (Fig.  3a, b). ELISA quantifications demon-
strated that CCR6+DN were the major source of IL-17F, 
produced IL-22 at levels similar to Th17 and Th1Th17, 
and CCL20 at levels higher and similar compared to 
Th17 and Th1Th17, respectively. In contrast, CCR6+DP 
produced low/undetectable levels of IL-17F, IL-22 and 
CCL20. Regarding the pro/anti-inflammatory profiles, 
(See figure on next page.)  
Fig. 3 CCR6+DN cells are a major source of IL‑17F, IL‑8, and IL‑21. Culture supernatants harvested from Th17, Th1Th17, and CCR6+DN (stimulated 
as in Fig. 1e) isolated from the peripheral blood of HIV‑uninfected individuals were screened for the expression of 34 T‑helper lineage‑specific 
cytokines using the Human Th1/Th2/Th17 Antibody Array C series (RayBiotec). a, b Shown are results from one experiment with matched Th17 
versus CCR6+DN and Th1Th17 versus CCR6+DN subsets: membrane blot (left panels) and relative density quantification (right panels). Results 
are representative of experiments performed with cells from two different donors: c, d Levels of IL‑17F, IL‑22, CCL20, IL‑10, IL‑13, TNF‑α, IL‑8, and 
IL‑21 were quantified by ELISA. Shown are results on matched Th17, Th1Th17, CCR6+DN, CCR6+DP, and CCR6− samples from different individuals 
(n = 3–7, mean ± SEM). Paired t‑Test p‑values are indicated in the graphs
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Th1Th17 were major TNF-α and IL-10 producers [5, 15, 
27], while CCR6+DN and CCR6+DP produced low lev-
els of TNF-α and moderate levels of IL-10 and IL-13. 
Nevertheless, CCR6+DN produced slightly more TNF-α 
compared to Th17 or CCR6+DP (Fig. 3c). Although not 
detected in our cytokine screen, IL-8, IL-21, and IL-2 
were quantified by ELISA. The highest levels of IL-8 and 
IL-21 were detected in CCR6+DN, while the highest lev-
els of IL-2 were detected in Th1Th17 (Fig. 3d). Thus, in 
contrast to CCR6+DP which exhibit modest Th17 fea-
tures, CCR6+DN are a major source of IL-17F, IL-8 and 
IL-21 and their pro-inflammatory profile is intermediate 
between that of Th17 and Th1Th17. Similar to CCR6+DP, 
CCR6+DN produce low IL-2 levels, a typical property of 
Th17 cells [15, 47].
CCR6+DN proliferate and produce IL‑17A in response to C. 
albicans
We further examined proliferation in response to typi-
cal Th17 (C. albicans) versus Th1 (CMV) antigens [5, 
48] using a monocyte-derived dendritic cell (MDDC)-
based antigen presentation assay (Fig. 4a). SEB was used 
to induce polyclonal proliferation. Sufficient numbers of 
CCR6+DP could not be sorted for these studies. Th17 
and Th1Th17 proliferated in response to C.albicans at 
levels superior to Th1, while Th1Th17 and Th1 but not 
Th17 proliferated in response to CMV. Similar to Th17, 
CCR6+DN proliferated in response to C. albicans but not 
CMV. All subsets proliferated similarly well in response 
to SEB (Fig. 4b). In response to C. albicans, the frequency 
of IL-17A+ cells was similarly high in CCR6+DN and 
Th17, low in Th1Th17, and background in Th1 (Fig. 4c). 
The frequency of IFN-γ+ within C. albicans-specific 
CCR6+DN was lower compared to Th1Th17 and Th1 
and higher compared to Th17. TNF-α was produced 
by all subsets at similarly high frequency.es. The fre-
quency of IL-17A+ cells co-expressing IFN-γ was dif-
ferent between the three C. albicans-specific CCR6+ 
subsets, while the majority of IL-17A+ cells in all sub-
sets co-expressed TNF-α (Fig. 4d). Notably, C. albicans-
specific CCR6+DN included relatively high frequencies 
of IL-17A+IFN-γ− and IL-17A+IFN-γ+ cells (Fig.  4e, f ). 
Thus, CCR6+DN share antigenic specificity and cytokine 
profiles with the previously characterized Th17 and 
Th1Th17.
CCR6+DN and CCR6+DP exhibit Th17‑commitment 
and lineage plasticity
The Th17 polarization flexibility/plasticity is well docu-
mented [2, 29], with Th17 being able to down-regulate 
RORγt and acquire Th1 features in response to Th1-
specific polarizing cues [6]. Therefore, we investigated 
the Th17-lineage commitment versus plasticity of the 
four CCR6+ subsets upon short (4  days) and long-term 
(14  days) culture under Th17- versus Th1-polarizing 
conditions (Fig.  5a). It is well-established that CM ver-
sus EM/TM are long-lived and acquire robust effector 
functions upon TCR triggering [32, 49]. Considering the 
superior production of Th17 cytokines by Th17-polar-
ized CM versus EM/TM (Additional file 4: S3 Figure) as 
well as the preponderance of CM cells (Fig.  1d), subse-
quent experiments were performed using CM isolated 
from HIV-uninfected individuals. Under Th17-condi-
tions, all four CCR6+ subsets produced IL-17A, IL-17F, 
IL-22 and TNF-α, while IFN-γ was highly expressed by 
Th1Th17, CCR6+DP and Th1 (Fig.  5b, c). The culture 
under Th17-conditions for 14 versus 4  days resulted in 
a remarkable increase in the proportion of cells produc-
ing Th17 effector cytokines. The culture under Th1- ver-
sus Th17-conditions resulted in a significant decrease in 
IL-17A, IL-17F and/or IL-22 expression by all CCR6+ 
subsets, with differences being more significant at day 14 
versus 4. This was associated with increased IFN-γ and 
TNF-α expression by CCR6+ subsets at day 4 (Fig.  5b) 
and increased IFN-γ within Th17 at day 14 (Fig. 5c). As 
expected [29], Th1 did not acquire Th17-features under 
Th17-conditions (Fig.  5b, c). Changes in the poly-func-
tionality of CM subsets cultured long-term under Th17 
versus Th1-conditions (Additional file  5: S4 Figure) 
were further evaluated using SPICE [50] (Additional 
file  6: S5 Figure). Under Th17-conditions, CCR6+ sub-
sets expressed 1–5 cytokines simultaneously. Th17 and 
(See figure on next page.) 
Fig. 4 CCR6+DN proliferate in response to C.albicans but not CMV. a FACS‑sorted T‑cell subsets isolated from the peripheral blood of HIV‑unin‑
fected individuals were stained with CFSE, co‑cultured with antigen‑loaded autologous monocyte‑derived dendritic cells (MDDC), and analyzed for 
their ability to proliferate (CFSElow) and produce cytokines. b Shown is the frequency of T‑cells proliferating in response to C. albicans hyphae, CMV, 
or SEB at day 5 post co‑culture. c Shown is the frequency of cytokine‑expressing T‑cells proliferating in response to C. albicans within each subset. 
d–f C. albicans‑specific T‑cells were further analyzed for the co‑expression of IL‑17A with IFN‑γ or TNF‑α. d Results are from one donor representative 
of results obtained with matched subsets from four different donors. (e–f) Shown is the frequency and MFI of C. albicans‑specific T‑cells express‑
ing IL‑17A either alone (IL‑17A+IFN‑γ−) (e) or in combination with IFN‑γ (IL‑17A+IFN‑γ+) (f). b–f The positivity gates were defined based on FMO 
controls. b, c and e, f Shown are results (mean ± SEM) on matched samples from n = 4 different. Paired t‑Test p‑values are indicated in the figures. 
ND not determined
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CCR6+DN expressed IL-17A mainly in combination with 
TNF-α alone or with TNF-α and IL-17F and/or IL-22, 
but at relatively low frequency in combination with IFN-
γ. Th1Th17 and CCR6+DP expressed IL-17A mainly 
in combination with IFN-γ and TNF-α, in the presence 
or absence of IL-17F or IL-22. The poly-functionality of 
CCR6+ subsets decreased under Th1- versus Th17-con-
ditions and was associated with diminished expression of 
Th17-cytokines and expansion of IFN-γ+TNF-α+ cells, 
representative of a Th1 profile. Thus, similar to Th17 
and Th1Th17, CCR6+DN and CCR6+DP amplified their 
Th17-features under Th17-conditions and acquired Th1-
features under Th1-conditions. Nevertheless, fractions of 
Th17 and CCR6+DN preserved their Th17 features under 
Th1-conditions, indicative that stably-committed Th17 
exist in humans.
CCR6+DN acquire CCR4/CXCR3 expression in response 
to Th17‑ or Th1‑polarizing signals
Finally, we investigated the stability/plasticity of CCR6, 
CCR4, and CXCR3 expression on CM Th17-subsets 
upon long-term exposure to Th17-/Th1-polarizing 
signals (Additional file  7: S6 Figure). Under Th17-
conditions, CCR6 was significantly down-regulated 
compared to Day 0, while culture under Th1- versus 
Th17-conditions was associated with a further decrease 
in CCR6 expression, mainly on CXCR3+Th1Th17 (Addi-
tional file  7: S6A Figure). However, CCR6 expression 
was preserved at >70 and >50 % under Th17- and Th1-
conditions, respectively (Additional file  7: S6A Figure). 
CCR4 expression was acquired by CXCR3+Th1Th17, 
CCR6+DN, and Th1 under Th17- or Th1-conditions 
(Additional file 7: S6B Figure). Notably, CCR6+DN cul-
tured under Th17- or Th1-conditions acquired CCR4 
at levels similar to CCR4+Th17 (Additional file  7: S6B 
Figure). In contrast, CCR4 expression decreased on 
CCR6+DP and CCR4+Th17 under Th17- or Th1-con-
ditions (Additional file  7: S6B Figure). CXCR3 expres-
sion was decreased on CXCR3+Th1Th17, CCR6+DP, 
and Th1 under Th17- or Th1-conditions, but increased 
on CCR6+DN and CCR4+Th17 under Th17-, and 
even more dramatically Th1-conditions. However, 
CXCR3 levels remained inferior to those detected on 
CXCR3+Th1Th17 and CCR6+DP (Additional file 7: S6C 
Figure). Analysis of CCR6 co-expression with CCR4 
or CXCR3 revealed that  ~70  % of CCR4+Th17 and 
CXCR3+Th1Th17 maintained their original phenotype 
under Th17-conditions (Additional file  7: S6D-E Fig-
ure). Fractions of CXCR3+Th1Th17 (mean: 21  %) and 
CCR6+DN (mean: 48 %) acquired a CCR6+CCR4+ phe-
notype (Fig. 6d), while Th17 (mean: 29 %) and CCR6+DN 
(mean: 24  %) acquired a CCR6+CXCR3+ phenotype 
(Additional file  7: S6E Figure). The CCR6+CCR4+ and 
CCR6+CXCR3+ phenotype was dramatically reduced 
within CCR6+DP under Th17- or Th1-condititions 
(Additional file 7: S6D-E Figure), with CCR6+DP acquir-
ing a CCR4−CXCR3+ but not CCR4+CXCR3− phe-
notype. These results reveal the remarkable flexibility 
of CCR6/CCR4/CXCR3 expression on Th17-subsets 
upon TCR triggering and in relation with the cyto-
kinic environment. Nevertheless, CCR6 expression was 
maintained on the majority of the four Th17-subsets, 
supporting the key role played by CCR6 in regulating 
tissue-specific homing of Th17-cells.
Th17‑polarized CCR6+DN and CCR6+DP are present in the 
blood of HIV‑infected individuals
To determine whether CCR6+DN and CCR6+DP exist 
in the blood of HIV-infected individuals and are stably 
Th17-polarized, the four memory CCR6+ T-cell subsets 
as well as Th1 cells were identified and then sorted by 
flow cytometry (as in Additional file  1: S1 Figure) from 
three chronically infected aviremic ART-treated individ-
uals (CI on ART) (Additional file 2: Table S2). The intra-
cellular expression of IL-17A and IFN-γ was assessed 
upon long-term culture in vitro. Briefly, cells were stimu-
lated via CD3/CD28 for 4 days and then cultured in the 
presence of IL-2 (Th0 polarizing conditions) for addi-
tional 9  days (Additional file  7: S6A Figure). Similar to 
HIV-uninfected donors, Th17 and CCR6+DN subsets 
from CI on ART individuals included a major fraction 
of IL-17A+IFN-γ− cells, while Th1Th17, CCR6+DN, 
and CCR6+DP exhibited a similar frequency of 
IL-17A+IFN-γ+ cells (Additional file 7: S6B-C Figure). Of 
note, similar to Th1, Th1Th17 and CCR6+DP included a 
major fraction of IL-17A−IFN-γ+ cells (Additional file 7: 
S6B-C Figure). In conclusion, the two newly identified 
Th17-polarized subsets, CCR6+DN and CCR6+DP, exist 
(See figure on previous page.) 
Fig. 5 Lineage commitment versus plasticity of the four CM CCR6+ subsets in vitro. FACS‑sorted CM (CD45RA−CCR7+) subsets isolated from the 
peripheral blood of HIV‑uninfected individuals were analyzed for the expression of lineage‑specific cytokines upon Th17/Th1‑polarization in vitro.  
a CM subsets were stimulated via CD3/CD28 and cultured under Th17‑ (IL‑1β, IL‑6, and IL‑23, and anti‑IL‑4 and anti‑IFN‑γ Abs) and Th1‑polarizing 
conditions (IL‑12 and anti‑IL‑4 Abs) for 4 and 14 days. Cells were stimulated with PMA and Ionomycin in the presence of Brefeldin A for 16 h. Intracel‑
lular staining was performed with cytokine‑specific Abs. b, c Shown are statistical analyses of cytokines expressed by the distinct CM subsets cul‑
tured for 4 (b) or 14 days (c) under Th17‑ (black bars) and Th1‑polarizing conditions (grey bars). Results (mean ± SEM) were generated with matches 
samples from n = 3 different donors. Paired t‑Test p‑values are indicated on the figures (Th17‑ versus Th1‑polarization)
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in the peripheral blood of HIV-infected individuals and 
exhibit a Th17- and Th1Th17-polarization profile.
CCR6+DN predominate in the blood of HIV‑infected 
individuals during ART
Circulating Th17 and Th1Th17 are depleted upon 
HIV-infection and their frequency is not restored 
with viral-suppressive ART [15, 16]. Thus, we investi-
gated alterations in the frequencies of CCR6+DN and 
CCR6+DP, relative to Th17 and Th17Th17, during HIV 
infection. In contrast to uninfected controls (Fig. 1b), the 
frequency of CCR6+DN in CI on ART individuals (Addi-
tional file 2: Table S2) was superior to that of Th17 and 
Th1Th17, while CCR6+DP were the least preponderant 
subset (Fig.  6a). As in uninfected controls (Fig.  1d), the 
four CCR6+ subsets from CI on ART individuals were 
enriched in cells with a CM phenotype (Fig.  6b). Simi-
lar to Th17 and Th1Th17 [15], the frequency of memory 
CCR6+DP was significantly reduced in CI on ART versus 
uninfected individuals (Fig. 6c). In contrast, no significant 
differences were observed in the frequency of CCR6+DN 
in CI on ART versus uninfected individuals. Similar 
observations were made when absolute cell counts were 
compared (Fig.  6d), indicative that CCR6+DN are pre-
served during HIV infection.
To further explore the preservation of CCR6+DN dur-
ing HIV infection, we performed longitudinal studies in 
HIV-infected individuals enrolled in the Montreal HIV 
Primary Infection (HPI) cohort. The dynamics of the 
four CCR6+ subsets were studied in relationship with 
plasma viral load at different time-points post-infection, 
before and after ART initiation (Fig.  6e, f ). Of note, in 
all five HIV+ individuals, CCR6+DN were the most pre-
dominant CCR6+ subset before and after ART initiation. 
ART initiation during the first year of infection effi-
ciently decreased plasma viral load to undetectable lev-
els in all individuals (Fig. 6e) and increased CD4 counts 
(Additional file 8: Table S3). We observed a tendency for 
increased Th17, Th1Th17 and CCR6+DN counts follow-
ing treatment (Fig. 6e), indicative of the positive effects of 
ART in increasing Th17 levels during early chronic infec-
tion. The counts of CCR6+DP were increased in 4/5 indi-
viduals following treatment but remained stable in one 
individual. Interestingly, the counts of CCR6+DN were 
superior at all time-points in 4/5 and 5/5 individuals, 
respectively, when compared to Th17 and CCR6+DP. In 
contrast, CCR6+DP counts were the lowest in all patients 
before/after ART initiation. These results demonstrate 
that CCR6+DP but not CCR6+DN are depleted in CI on 
ART individuals.
CCR6+DN are enriched in the lymph nodes of HIV‑infected 
individuals on ART
Blood CCR6+DN express Tfh markers as demonstrated 
by transcriptional profiling (Fig. 2) and IL-21 quantifica-
tion (Fig.  3D). Tfh are localized in the B cell follicles of 
secondary lymphoid organs and are major targets for 
HIV infection [51, 52]. Access to inguinal lymph nodes 
from three HIV-infected individuals on ART (Additional 
file 8: Table S2; CI 36, CI 37, CI 38) allowed us to reveal 
that CCR6+DN represent the most frequent CCR6+ 
T-cell subset in the lymph nodes (Fig.  7). These results 
suggest that peripheral blood CCR6+DN recirculate pref-
erentially through lymph nodes and may include a frac-
tion of Tfh.
CCR6+DN are permissive to viral infection in vitro and in 
HIV‑infected individuals
We and others previously demonstrated that Th17 and 
Th1Th17 cells are permissive to HIV infection [15, 16]. 
Thus, CCR6+DN and CCR6+DP were compared to Th17 
and Th1Th17 in terms of HIV permissiveness in  vitro 
and ability to carry proviral DNA in HIV-infected indi-
viduals. The HIV co-receptor CCR5 was expressed at low 
levels on CCR6+DN, similar to Th17, and high levels on 
CCR6+DP, similar to Th1Th17. CXCR4 expression was 
similarly high on all subsets (Fig. 7a). Exposure to replica-
tion-competent R5 HIV strain ADA8 demonstrated that 
CCR6+DN and CCR6+DP, similar to Th17 and Th1Th17, 
are permissive to HIV infection in  vitro (Fig.  7b). Fur-
ther, Th17, Th1Th17, CCR6+DN and/or CCR6+DP were 
isolated from three recently-infected viremics untreated 
individuals (RI) (Additional file 8: Table S2) for integrated 
HIV-DNA quantification. Results in Additional file 9: S7 
Figure demonstrate that similar to Th17 and Th1Th17, 
CCR6+DN carry integrated HIV-DNA in all three donors 
(See figure on next page.) 
Fig. 6 CCR6+DN distinguish from the other Th17‑subsets by superior frequency/counts in CI on ART individuals. a PBMCs from CI on ART individu‑
als (n = 20; Additional file 8: Table S2) were stained as in Fig. 1. Shown is the relative frequency of the four CCR6+ subsets in CI on ART individuals. 
Paired t‑Test p‑values are indicated on the figures. Horizontal bars indicate median values. b Shown are median frequencies of CM, TM, and EM within 
each CCR6+ subsets from CI on ART (n = 10). Shown is the frequency (c) and counts (d) of the four CCR6+ subsets in CI on ART versus uninfected 
individuals. Cell counts were calculated taking into account their frequency within the total CD4+ T‑cell fraction. e The dynamics of CCR6+ subset 
counts were investigated longitudinally in n = 5 HIV‑infected individuals from the Montreal HIV Primary infection cohort (Additional file 8: Table S3), 
in relationship with plasma viral load, before and after ART initiation (grey). f Shown are statistical analysis for differences in cell counts between the 
four CCR6+ subsets (n = 5 HIV‑infected individuals) using Friedman test and the post‑test Dunn’s multiple comparison and Wilcoxon t test
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tested, at relative levels varying between donors but 
superior to levels in naive T-cells. Thus, CCR6+DN are 
permissive to HIV infection in vitro and in vivo (Fig. 8).
CCR6+DN carry replication‑competent integrated HIV‑DNA 
in CI on ART individuals
Recent evidence from our group (Gosselin et al, unpub-
lished observations) and others [26], support the con-
tribution of long-lived Th17 cells to HIV reservoir 
persistence under ART. Thus, we sought to determine 
whether CCR6+DN harbor replication-competent HIV 
reservoirs in HIV-infected individuals with undetect-
able viral load under ART (Additional file  8: Table S2). 
The four CCR6+ T-cell subsets as well as Th1 cells were 
sorted by flow cytometry as in S1 Figure. Similar to the 
other cell subsets, CCR6+DN harbored integrated HIV-
DNA ex vivo (Fig. 9a) and produced measurable levels of 
viral particles after stimulation via CD3/CD28 for 4 days 
(Fig. 9b), indicating that these integrated genomes can be 
induced to produce HIV virions. To further determine 
Fig. 7 CCR6+DN are predominant in lymph nodes of HIV‑infected individuals receiving ART. a, b Matched PBMCs and inguinal lymph node cells 
from three CI on ART individuals (CI 36, CI 37, CI 38; Additional file 8: S2 Table) were stained with a cocktail of fluorochrome‑conjugated CD3, CD4, 
CD45RA, CCR4, CXCR3, CCR6, and CCR7 Abs. A viability staining was used to exclude dead cells. Viable memory CD4+ T‑cells (CD3+CD4+CD45RA−) 
expressing CCR6 were analyzed for their differential expression of CCR4 and CXCR3. The four CCR6+ subsets including Th17, CCR6+DP, CCR6+DN, 
and Th1Th17 were identified in both PBMCs and cells from lymph nodes. a Shown is the phenotype of PBMCs (upper panels) and lymph node cells 
(lower panels) in one representative donor. b Shown are statistical analysis of the frequency of CCR6+ subsets in the lymph node (n = 3). Paired 
t‑Test p‑values are indicated on the figures
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the replication competency of HIV virions, we per-
formed a modified viral outgrowth assay [53] that con-
sisted in the culture of CD3/CD28-activated cells for 
thirteen days in the presence of IL-2 (as in Additional 
file 1: S6A Figure). Results in Fig. 9c demonstrate intra-
cellular expression of HIV-p24 in CCR6+DN from 3/3 
CI on ART individuals, as well as the co-expression of 
HIV-p24 with IL-17A. The HIV-24 expression was also 
observed at various frequencies in Th17, Th1Th17 and 
Th1 cells in 2/3 CI on ART individuals Fig. 9c. Interest-
ingly, HIV-p24 was detected in CCR6+DP only 1/3 CI on 
ART individuals. Of note, in preliminary experiments, 
intracellular HIV-p24 was detected when cells were cul-
tured in the absence but not the presence of antiretroviral 
drugs (ARVs: AZT (180 nM), Efavirens (100 nM), Ralte-
gravir (200 nM)), suggesting that cell-to-cell HIV spread-
ing occurred in culture (data not shown). Noteworthy, 
the HIV-p24+ CCR6+DN cells probed to be highly poly-
functional in terms of IL-17A, IL-22, IFN-γ and TNF-α 
expression (Fig. 9d; Additional file 10: S8 Figure). Finally, 
we observed that a fraction of the HIV-p24+ CCR6+DN 
cells were able to proliferate when cultured for addi-
tional 5 days in the presence of IL-2 or CD3/CD28 Abs 
(Fig. 9e). Together these results support the contribution 
of CCR6+DN cells to HIV persistence during ART.
Discussion
The concept of Th17 pathogenicity is well defined in 
the context of autoimmunity [18, 19, 21]. During HIV-1 
infection, Th17 cells may be considered pathogenic 
because they are permissive to HIV-1 and subsequently 
depleted [15, 16]. Alternatively, long-lived Th17 cells 
[25, 28, 29] may carry integrated HIV-DNA and contrib-
ute to viral reservoir persistence under ART (Gosselin 
et al, unpublished observations) [26]. In this manuscript 
we used a systems biology approach to characterize the 
heterogeneity of memory subsets expressing the Th17 
marker CCR6 at homeostasis and during HIV-1 infec-
tion. We reveal the existence of two new subsets of Th17-
polarized CCR6+ T-cells, CCR6+DN (CCR4−CXCR3−) 
and CCR6+DP (CCR4+CXCR3+), that share functional 
characteristics with the previously characterized Th17 
and Th1Th17 [5, 15, 16] in terms of lineage-specific 
cytokines, antigenic specificity, lineage specification ver-
sus plasticity and HIV permissiveness. Genome-wide 
transcriptional profiling revealed a unique molecular sig-
nature in CCR6+DN, suggesting they represent an early 
stage of Th17 differentiation. In contrast to the other 
Th17-polarized subsets, the CCR6+DN was the most 
predominant in the blood and the lymph nodes of HIV-
infected subjects with undetectable plasma viral load 
Fig. 8 CCR6+DN and CCR6+DP subsets are permissive to HIV infection in vitro. a PBMCs from healthy individuals were stained with a cocktail of 
fluorochrome‑conjugated CD3, CD4, CD45RA, CCR4, CXCR3, CCR6, and CCR5 or CXCR4 Abs. The gating strategy for the identification of distinct 
CCR6+ and CCR6− T‑cell subsets was designed as in Fig. 1a. The frequency of cells expressing CCR5 (left panel) and CXCR4 (right panel) was analyzed 
within the Th17, Th1Th17, CCR6+DN and CCR6+DP subsets. Paired t‑Test p‑values are indicated on the figures. Horizontal bars indicate median 
values. b Memory CCR6+ subsets from three HIV‑uninfected subjects were sorted and stimulated via CD3/CD28 for 4 days, as in Fig. 1e. Cells were 
exposed to a highly infectious R5 strain HIV‑ADA8. Levels of HIV‑p24 were quantified by ELISA in cell supernatants at day 3 posy‑infection
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under ART. Finally, we demonstrated that CCR6+DN 
carry replication competent HIV reservoirs in ART-
treated individuals. Our results support the concept that 
long-lived Th17 cells, i.e., CCR6+DN, contribute to HIV 
persistence during ART.
Similar to Th17 cells, CCR6+DN were a major source 
of IL-17A, while CCR6+DP and Th1Th17 cells pro-
duced low IL-17A levels. Nevertheless, CCR6+DN and 
CCR6+DP expressed both typical Th17 transcripts (i.e., 
IL-26, CCL20, IL-22, IL-23R, RORC, IL-17F, RORA, 
KLRB1/CD161, IL6R [3]) and potentially new Th17 
markers (CXCR6, PTPN13, MAP3K4, S100A4, CD96, 
Ly9, KLF2, LGMN, TNFRSF25, ANTXR2, and CTSH). 
PTPN13, a phosphatase associated with Fas [54], was 
previously identified as Th17-specific [21, 55] and may 
contribute to the regulation of cell activation/apoptosis. 
ARNTL, a component of the circadian clock machin-
ery, was proved to regulate RORγt expression and Th17 
development in mice [56]. Finally, the expression of 
ANTXR2 is consistent with recent findings that Th17 
cells govern adaptive immune responses against Bacillus 
anthracis [57].
Despite several transcriptional similarities, CCR6+DN, 
CCR6+DP and Th17 expressed distinct molecular signa-
tures linked to specific pathways and biological processes. 
CCR6+DN were enriched in molecules associated with 
lymph node chemotaxis (CCR7, CXCR5, CXCL13, SELL, 
SIRP1, JAM3, AIF1). In contrast, Th17 and CCR6+DP 
expressed molecules related to homing into peripheral 
tissues including the gut (integrin β7 or CXCR3), skin 
(CCR2, CCR4) and cervix (integrin β1). Several signal-
ing pathways involved in Th17 differentiation, including 
IL-6, phospholipase C, April and NFAT, were upregu-
lated in CCR6+DN versus Th17 and/or CCR6+DP. 
CCR6+DN expressed higher levels of STAT3 mRNA and 
were enriched in other Th17-associated markers includ-
ing IL-17F, RORA [58], IL-23R [43], SOSC3 [59], TIM3 
[60] and CD26/DPP4 [61]. STAT3 is one of the first tran-
scription factors to be up-regulated within the first hours 
of Th17 polarization [62]. Cell fate mapping experiments 
(See figure on previous page.)  
Fig. 9 CCR6+DN carry replication competent HIV‑DNA. a, b The four memory CCR6+ subsets as well as Th1 cells from PBMCs of chronically infected 
receiving viral suppressive ART (CI on ART) individuals were sorted by FACS. a Levels of integrated HIV‑DNA were quantified by nested real‑time 
PCR in sorted cells ex vivo (mean ± SD of triplicate wells; n = 4 CI on ART individuals). b, c FACS‑sorted memory subsets were stimulated via CD3/
CD28 and cultured as described in S6A Figure legend for up to 14 days. b HIV‑RNA levels were quantified by real‑time RT‑PCR in culture superna‑
tant of cells stimulated via CD3/CD28 for 4 days (n = 4 CI on ART individuals). c, d At day 13, cells were stimulated with PMA and Ionomycin in the 
presence of Brefeldin A for 6 h. Intracellular staining was performed with cytokine‑specific Abs and HIV‑p24. c Shown are flow cytometry dot plots 
illustrating the co‑expression of IL‑17A and HIV‑p24 (n = 3). d Shown are pie charts representations generated with the SPICE software illustrating 
the poly‑functional profile of HIV‑p24+ CCR6+DN cells; all possible combinations of one (blue), two (green), three (orange) and four (yellow) or no 
(purple) cytokines are depicted (n = 3 CI on ART individuals). e At day 13, CCR6+DN subsets were stained with CFSE and cultured for 5 additional 
days in the presence of either IL‑2 (5 ng/ml) or CD3/CD28 (1 µg/ml). Cells expressing or not intracellular HIV‑p24 were then analyzed for their ability 
to proliferate (CFSElow)
demonstrated IL-17F is expressed during early stages of 
Th17 differentiation [33]. Further, CCR6+DN were found 
to express a stem-cell-like molecular signature including 
RORA, STAT3, LEF1, MYC and TERC [25, 46, 63, 64] 
as well as the NANOG signaling pathway, important for 
the maintenance of stem cells [39]. LEF1 and MYC char-
acterize long-lived Th17 cells with self-renewal proper-
ties [25]. TERC is linked to telomerase activity, which is 
up-regulated in stem cells, cancer cells and proliferating 
lymphocytes [46]. In contrast, CCR6+DP [56] together 
with Th17 expressed high levels of LMNA, a senescence 
marker [34]. These findings feed the idea that CCR6+DN 
versus Th17 and CCR6+DP represent a less advanced 
stage of Th17 differentiation with superior survival 
potential.
In addition to IL-17F, CCR6+DN are distinguished 
from the other CCR6+ subsets by their relatively high 
production of IL-8 and IL-21. IL-8 is critical for neutro-
phil recruitment at inflammatory sites [65], indicative 
of superior effector functions for CCR6+DN. IL-21 is 
the hallmark cytokine for follicular helper T cells (Tfh) 
[44]. IL-21 up-regulates expression of the Tfh-specific 
transcription factor BCL6 and the chemokine receptor 
CXCR5 [66]. Consistently, CCR6+DN express the highest 
levels of BCL6 and CXCR5 mRNA, and are also enriched 
in ASCL2 mRNA, another Tfh-specific transcription 
factor [45]. Thus, CCR6+DN cells share Tfh features. 
This is in line with a proposed differentiation model in 
which Tfh development occurs subsequent to Th1, Th2 
or Th17 polarization [44]. Similar to Th17 but in contrast 
to Th1Th17 [15], CCR6+DN and CCR6+DP produce low/
undetectable levels of IL-2, a cytokine known to promote 
cell survival [67]. IL-21 acts as a survival factor for Th17 
cells [68]. IL-21 supplementation leads to the restora-
tion of IL-17A-producing cells in SIV-infected macaques 
[68]. Therefore, IL-21 produced by CCR6+DN may act in 
autocrine manner to support superior survival of these 
cells and compensate for their limited IL-2 expression.
Th17 cells mediate immunity against pathogens local-
ized at barrier surfaces including C. albicans [3, 5]. 
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Here, we reveal that CCR6+DN, similar to Th17, prolif-
erate and produce IL-17A in response to C.albicans but 
not CMV. We also observed proliferation of Th1Th17 
and Th1 in response to C. albicans and CMV. These 
results are consistent with recent studies from Becat-
tini et  al. in which Th17, Th1Th17 and Th1 share 
C.albicans clonotypes, while expressing distinct effec-
tor cytokines [27]. Clonotype sharing between Th17 
subsets is consistent with previous reports on the 
acquisition of Th1 features by Th17 cells under inflam-
matory conditions [29]. Whether CCR6+DN and Th17 
share C.albicans clonotypes remains to be investigated. 
The antigenic specificity of CCR6+DP was not tested in 
our study. However, Becattini et al. identified a popula-
tion similar to CCR6+DP that shared with Th1Th17 M. 
tuberculosis clonotypes [27], thus suggesting a potential 
Four distinct Th17 subsets in humans
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Fig. 10 New insights into the heterogeneity of human Th17 cells at homeostasis and during ART‑controlled HIV‑1 infection. In this work we 
identified two new subsets of CCR6+ T‑cells, CCR6+DN/CCR4−CXCR3− and CCR6+DP/CCR4+CXCR3+, that share Th17 features with the previously 
described Th17/CCR4+CXCR3− and Th1Th17/CCR4−CXCR3+ [5]. Despite these similarities, CCR6+DN distinguished from the other three subsets 
by superior their ability to produce Th17 effector cytokines (e.g., IL‑17F, IL‑8, and IL‑21) and their predominant frequency/counts in the blood and 
lymph nodes HIV‑infected individuals receiving ART. Finally, we demonstrate that CCR6+DN harbor replication‑competent HIV‑DNA. Thus, we reveal 
the existence in humans of four Th17‑polarized CCR6+ subsets that represent distinct stages of Th17 differentiation, with CCR6+DN being the most 
predominant and contributing to HIV reservoir persistence under ART
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differentiation relationship between CCR6+DP and 
Th1Th17.
In contrast to CCR6−, CCR6+ T-cells are prone to 
express Th17 functions [10]. Consistently, the frequency 
of cells expressing IL-17A, IL-17F and IL-22 was dra-
matically increased in all CCR6+ subsets upon long-term 
exposure to Th17-polarizing signals. Notably, CCR6+DN 
and Th17 were distinguished from CCR6+DP and 
Th1Th17 by their superior IL-17A/IL-17F and reduced 
IFN-γ expression. Th17 cells are known to be extremely 
plastic and can dedifferentiate into other lineages [29]. 
As such, all Th17 subsets diminished expression of Th17 
cytokines and enhanced IFN-γ expression in response to 
Th1-polarizing signals. This is consistent with other stud-
ies in mice and humans demonstrating suppression of 
Th17 effector cytokines upon IL-12 exposure [6, 69]. Our 
results reveal that CCR6+DN and CCR6+DP, together 
with Th17 and Th1Th17, are four distinct Th17-com-
mited subsets that exhibit lineage plasticity. Noteworthy, 
a fraction of CCR6+DN and Th17 preserved production 
of Th17 cytokines under Th1 conditions, providing evi-
dence that stably-committed Th17 cells exist in humans, 
as previously predicted [2]. Our results also confirm the 
stability of the Th1 transcriptional program [29].
The chemokine receptors CCR6, CCR4, and CXCR3 
mediate T-cell recruitment into gut-associated lym-
phoid tissues [7, 70], skin [71], and various other inflam-
matory sites [72]. We observed that the expression of 
these receptors represents stable signatures for a frac-
tion of CM Th17-subsets upon exposure to Th17/Th1-
polarization signals. In contrast to CCR4 and CXCR3, 
the expression of CCR6 was particularly stable under 
Th17-polarizing conditions, consistent with the iden-
tification of stable epigenetic mechanisms involved in 
the regulation of CCR6 expression [73]. CCR6 expres-
sion was mainly decreased upon exposure to Th1-polar-
izing cytokines, consistent with the reported ability 
of IL-12 to down-regulate CCR6 [74]. The expression 
of CCR4 and CXCR3 was stable on >70  % Th17 and 
>80  % Th1Th17, respectively, regardless of the polari-
zation conditions. Interestingly, CCR6+DN cultured 
under Th17- or Th1-conditions acquired a “classical” 
Th17-phenotype (CCR6+CCR4+), while CXCR3, a 
marker for Th1Th17 and Th1-cells [5, 15], was similarly 
acquired by CCR6+DN and Th17 under Th17-/Th1-con-
ditions. It is reported that Th1Th17-cells derive from 
Th17-cells that acquired Th1-features under inflamma-
tory conditions [75–77]. Our results demonstrate that 
CCR6+DN acquire Th17 and/or Th1Th17 phenotypic 
features. In contrast to CCR6+DN, a significant fraction 
of CCR6+DP lost CCR4 and/or CXCR3, regardless of 
polarization conditions, and acquired a Th1Th17 but 
not Th17 phenotype. All these findings reveal flex-
ibility in the expression of CCR6, CCR4 and/or CXCR3 
by these Th17-subsets, flexibility that may be relevant 
for their differential recruitment into various tissues. 
This flexibility suggests a developmental relationship 
between these four Th17-subsets via molecular mecha-
nisms that remain to be further investigated.
Of particular importance, we demonstrate that the 
four CCR6+ T-cell subsets exist in the peripheral blood 
of HIV-infected individuals and exhibit a Th17-polariza-
tion profile similar to subsets from uninfected individu-
als. The CCR6+DN were the most preponderant among 
Th17 subsets in the peripheral blood of ART-treated 
individuals as their frequency/counts were preserved at 
levels similar to uninfected individuals. Furthermore, in 
a longitudinal follow-up in five HIV-infected individuals, 
CCR6+DN proved to be the most predominant CCR6+ 
subset before/after ART initiation. This raised the possi-
bility that CCR6+DN are resistant to infection.
In contrast to the above prediction, we demon-
strated that all four Th17 subsets, including CCR6+DN, 
were permissive to HIV infection in  vitro and in  vivo. 
CCR6+DN and CCR6+DP expressed the HIV corecep-
tors CCR5 and CXCR4 at levels similar to Th17 and 
Th1Th17, respectively. Accordingly, all Th17 subsets were 
permissive to HIV in  vitro. Furthermore, CCR6+DN, 
Th17 and Th1Th17 harbored proviral HIV-DNA in 
RI individuals, indicative of their HIV permissiveness 
in  vivo. Of particular interest, all four CCR6+ subsets 
were found to carry relatively high levels of integrated 
HIV-DNA in virologically suppressed ART-treated indi-
viduals. We further demonstrated that viral transcription 
and production, reflected by the detection of HIV-RNA 
in cell culture supernatants, occurred in all four Th17 
subsets, including CCR6+DN cells. Finally, we demon-
strate active viral replication in CCR6+DN cells cultured 
for 13 days under Th0 polarizing conditions in vitro. Of 
note, HIV-p24+ CCR6+DN cells from CI on ART indi-
viduals co-expressed IL-17A and were highly poly-func-
tional, and a fraction of them were able to proliferate in 
response to repetitive IL-2 stimulation or TCR trigger-
ing in  vitro. These results support the contribution of 
CCR6+DN cells to HIV reservoir persistence under ART. 
This is consistent with a model in which integrative infec-
tion is compatible with survival [78] and CCR6 triggering 
via CCL20 promotes HIV latency [79] and suggests that 
permissiveness to HIV integration compatible with sur-
vival represents a new previously unrecognized feature 
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of pathogenic Th17 cells during HIV infection. Future 
functional validations on the host cell machinery com-
ponents used by HIV to insure its persistence in specific 
Th17 subsets such as CCR6+DN cells are important for 
the design of new targeted “shock and kill” strategies. 
Alternatively, other strategies may involve the interfer-
ence with the CCL20-CCR6 interaction using small 
molecule inhibitors that may limit CCL20-mediated 
establishment of HIV latency in CCR6+ T-cells, consist-
ent with the model proposed by Lewin et al. [79]. The fact 
that CCR6+DN exhibit CM features and are located in 
the lymph nodes emphasized the complexity/challenge of 
HIV eradication.
Our results that CCR6+DN express Tfh markers are in 
line with a recent study demonstrating the restoration of 
CCR6+ T cells expressing a Tfh signature (CCR7highCX-
CR5highPD-1high) under ART [81]. CD4+ T cells with CM 
features constitute the main reservoir of latent HIV [82]. 
Indeed, we demonstrate that CCR6+DN are enriched in 
cells with CM phenotype and they are the most predomi-
nant CCR6+ T-cell subset in the inguinal lymph nodes 
of three ART-treated individuals. Future studies are 
required to determine whether CCR6+DN from lymph 
nodes exhibit Tfh features and carry replication-compe-
tent HIV reservoirs.
Conclusions
In summary, we demonstrated the existence in humans of 
four distinct Th17-polarized CCR6+ CD4+ T-cell subsets 
with differential expression of CCR4 and CXCR3, includ-
ing two newly characterized CCR6+DN and CCR6+DP 
populations (Fig.  10). The existence of multiple Th17 
subsets with distinct trafficking potential and func-
tional properties might allow defenses at barrier surfaces 
including the gut, while maintaining a pool of long-lived 
CM Th17 cells, i.e., CCR6+DN, that recirculate across 
lymph nodes. HIV-1 appears to exploit this heterogene-
ity for its replication and persistence. Considering altera-
tions in the Th17 pool during early acute phases of HIV-1 
infection [83], together with the long-lived properties of 
some Th17 cells [25, 28, 29], new Th17-specific therapeu-
tic strategies are needed to prevent HIV reservoir estab-
lishment during primary infection and to induce latency 
reversal during the chronic phase. Outside the HIV field, 
this work provides a new original understanding of the 
functional heterogeneity of Th17 cells at molecular level 
that is critical for designing new therapeutic strategies 
to manipulate cellular features during other pathological 
conditions associated with impaired or exacerbated Th17 
responses.
Methods
Study individuals and biological samples
Human individuals were recruited at the Montreal Chest 
Institute, McGill University Health Centre, and the Uni-
versite de Montreal Hospital Centre (CHUM), Montreal, 
Quebec. Peripheral blood mononuclear cells (PBMCs) 
were collected by leukapheresis and cryopreserved until 
use [15]. Cytomegalovirus (CMV) infection was deter-
mined upon detection of CMV-specific Abs using chemi-
luminescent microparticle immunoassay (CMIA) [84]. In 
parallel, matched blood and inguinal lymph node sam-
ples were collected from three HIV-infected individuals 
from the SCOPE study (UCSF School of Medicine, CA, 
USA) who were on stable ART with undetectable viremia 
(<40 HIV RNA copies/ml) for at least 8 years. After care-
ful removal of the surrounding fatty tissue, lymph nodes 
were mechanically disrupted using frosted glass slides. 
The single cell suspension obtained was filtered and ben-
zonase digested (25 U/mL) before to be used for flow 
cytometry analysis.
Antibodies and polychromatic flow cytometry analysis
Detailed description available in Online supplemental 
material.
Magnetic (MACS) and fluorescence activated cell sorting 
(FACS)
Total CD4+ T-cells were sorted from PBMCs by negative 
selection using magnetic beads (Miltenyi Biotec) [15], 
and stained with CD45RA, CCR4, CXCR3 and CCR6 
Abs, and a cocktail of FITC–conjugated CD8, CD19, 
and CD56 Abs. Memory CD4+ T-cells (CD45RA−) with 
differential expression of CCR6, CCR4 and/or CXCR3 
were sorted by FACS (BDAria II; BD Biosciences): 
CXCR3−CCR4+ (CCR4+Th17 [5, 15]), CXCR3+CCR4− 
(CXCR3+Th1Th17 [5, 15]), CXCR3−CCR4− (CCR6+DN), 
and CXCR3−CCR4− (CCR6+DP). Total CCR6− or 
CXCR3+CCR4− (Th1 [5, 15]) subsets were sorted in par-
allel. Sorting gates were set on FITC- to exclude CD8+ 
T-cells, CD19+ B-cells, and CD56+ NK-cells. For specific 
experiments, central (CM, CD45RA−CCR7+) and effec-
tor memory (EM, CD45RA−CCR7−) subsets with dif-
ferential expression of CCR6, CCR4 and/or CXCR3 were 
sorted. Sorting gates were set based on FMO controls 
[15]. Quality control analysis post-sort indicated an aver-
age purity >95 % (Additional file 1: S1 Figure).
Genome‑wide transcription profiling
Matched memory CD4+ T-cell subsets were iso-
lated by FACS from different HIV-uninfected donors 
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stimulated with immobilized CD3 and soluble CD28 
(1  µg/ml) for 4  days. Total RNA was isolated using 
RNeasy columns kit (Qiagen) according to the manu-
facturer’s protocol. RNA quantity was determined by 
Pearl nanophotometer (Implen, Germany) (106 cells 
yielded 1–5  µg RNA). Genome-wide analysis of gene 
expression was performed on total RNA by Génome 
Québec Innovation Centre (Montreal, Qc, Canada). 
Briefly, the quality of total RNA was tested using the 
Agilent 2100 Bioanalyzer chip. High quality RNA was 
reverse transcribed and hybridized on the Illumina 
HumanHT-12 v4 Expression BeadChip providing cov-
erage for more then 47,000 transcripts and known 
splice variants across the human transcriptome. The 
expression of differentially expressed genes was iden-
tified as previously described [55]. The entire micro-
array dataset and technical information requested by 
Minimum Information About a Microarray Experi-
ment (MIAME) are available at the Gene Expression 
Omnibus (GEO) database under accession number 
GSE66972. Differentially expressed genes (cut-off 1.3-
fold; p < 0.05) were classified through Gene Ontology 
using the NetAffx web-based application (Affymetrix), 
while differentially expressed pathways were identified 
using Ingenuity Pathway Analysis (IPA) and Gene Set 
Variation Analysis (GSVA). Corresponding heat maps 
for biological function categories were generated using 
programming language R [55].
Real‑time RT‑PCR
One step SYBR Green real-time RT-PCR was carried out 
in a LightCycler 480 II (Roche) using Qiagen reagents 
according to manufacturer’s recommendations, as pre-
viously described [55, 85]. Briefly, STAT3, BCL-6, Lef1, 
and Terc primers were purchased from Qiagen (Quanti-
Tect Primer Assay). The expression of each gene was nor-
malized relative to the internal control 28S rRNA levels 
(forward 5′-CGAGATTCCTGTCCCCACTA-3′; reverse 
5′-GGGGCCACCTCCTTATTCTA-3′ (IDT [85]). Sam-
ples without template or without reverse transcriptase 
were used as negative controls. Each RT-PCR reaction 
was performed in triplicata.
Cytokine screening and ELISA quantification
Cell culture supernatants were screened for the expres-
sion of 34 cytokines using the Human Th1/Th2/Th17 
Antibody Array C series (RayBiotec, Norcross, GA), 
as previously described [86]. Cytokine levels were 
quantified by ELISA using commercial kits for IL-10, 
IL-13, IL-17A, IL-17F, IL-21, IL-22, IFN-γ, TNF-α 
(Ebioscience) as well as CXCL8/IL-8 and CCL20 (R&D 
Systems).
Intracellular cytokine staining
Intracellular expression of cytokines was measured by 
FACS [87] using the BD Cytofix/Cytoperm kit (BD Bio-
sciences) and specific Abs (See table above). Analysis was 
performed using Diva and FlowJo. Polyfunctional profiles 
were analyzed using the SPICE (version 5.3; provided by 
Mario Roederer, VRC/NIAID/NIH) [50].
Antigen presentation assay
Cell proliferation was measured using the carboxy fluor-
oscein succinimidyl ester (CFSE) dilution assay [87], 
following co-culture with antigen-loaded autologous 
monocyte-derived dendritic cells (MDDC). Briefly, 
monocytes isolated from PBMCs by negative selection 
using magnetic beads (Miltenyi Biotec) [86] were dif-
ferentiated into MDDC in the presence of GM-CSF and 
IL-4 (20 ng/ml; R&D Systems). MDDCs were loaded with 
SEB (25 ng/ml; Toxin Technologies), CMV-pp65 peptide 
pool (1  μg/ml; Miltenyi) or Candida albicans hyphae 
LAM-1 [88] (25  µl protein lysate [87]) for one hour at 
37  °C and cocultured with FACS-sorted CFSE-loaded 
T-cell subsets. MDDC:T-cell cocultures (1:4 ratio) were 
maintained for 5 days at 37 °C. MDDC:T-cell co-cultures 
were stained with CD3 (T-cell marker) and CD1c (DC 
marker). Proliferating T-cells were identified as cells with 
a CFSElowCD3+CD1c− phenotype. In parallel, MDDC:T-
cell co-cultures were stimulated with PMA and Ionomy-
cin in the presence of brefeldin A and the expression of 
cytokines in proliferating T-cell subsets was quantified 
by FACS upon intracellular staining with specific anti-
cytokine Abs (See table above). Intracellular expression 
of cytokines was quantified by FACS [87].
Th17 versus Th1 polarization
Cells were stimulated via CD3/CD28 and cultured under 
Th17-polarizing conditions (IL-1β (10 ng/ml), IL-6 (50 ng/
ml), and IL-23 (40 ng/ml), and anti-IL-4 (1 μg/ml) and anti-
IFN-γ Abs (10  μg/ml) (R&D Systems)) or Th1-polarizing 
conditions (IL-12 (5  ng/ml) (R&D Systems) and anti-IL-4 
Abs (1 μg/ml)) for 4 days. Cells were washed and plated in 
media containing the Th17- or Th1-polarization cocktails 
together with recombinant IL-2 (5 ng/ml) for 10 additional 
days. Polarizing cytokines were replenished every 2–3 days 
and cells were split to optimal density (<2 × 106 cells/ml).
HIV infection in vitro
FACS-sorted memory CCR6+ T-cell subsets were acti-
vated for 4  days via CD3/CD28 (1  μg/ml) and then 
exposed to HIV-1 ADA8 (50  ng HIV-p24 per 106 cells) 
for 3  h at 37  °C. Extensive washing was performed to 
remove unbound HIV. Cells (106 cells per ml) were cul-
tured in media containing FBS (10 %) and IL-2 (5 ng/ml; 
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R&D Systems). Cell culture supernatants were harvested 
at day 3 post-infection and HIV replication was meas-
ured by HIV-p24 ELISA.
Real‑time PCR quantification of integrated HIV‑DNA
The quantification of integrated HIV-DNA was performed 
as we previously described [15, 82]. Briefly, cells were 
digested in a proteinase K buffer (Invitrogen), and 105 
cells/15  µl lysate were used per amplification. Integrated 
HIV-DNA was amplified first (12 cycles) using two out-
ward-facing Alu primers and one HIV LTR primer tagged 
with a lambda sequence; the CD3 gene was amplified 
in the same reaction. The HIV and CD3 amplicons were 
then amplified in separate reactions (Light Cycler 480, 
Roche Diagnostics). The HIV-DNA was amplified using 
a lambda-specific primer and an inner LTR primer in the 
presence of two fluorescent probes specific for HIV LTR. 
The CD3 DNA was amplified using inner primers and two 
fluorescent probes specific for CD3. Amplification reac-
tions were carried out with Light Cycler 480 Probe Master 
Mix (Roche) and Taq Polymerase (Invitrogen). The ACH2 
cells carrying one copy of integrated HIV-DNA per cell 
(NIAIDS reagent program) were used as standard curve.
HIV reactivation assay
Highly pure matched memory CD4+ T-cell subsets were 
isolated by FACS from different CI on ART individuals 
and stimulated with immobilized CD3 and soluble CD28 
Abs (1 µg/ml) for 4 days. Cells were washed and plated in 
media containing recombinant IL-2 (5 ng/ml) for 9 addi-
tional days. IL-2 was replenished and cells were split to 
optimal density (<2 × 106 cells/ml) every 3 days. At day 
13, cells were stimulated with PMA and Ionomycin in the 
presence of Brefeldin A for 6 h. Intracellular staining was 
performed with cytokine-specific Abs and HIV-p24. Cell 
culture supernatants were collected at day 4, 7, 11, and 
13 post-TCR triggering and used for the quantification of 
HIV-RNA and/or HIV-p24 levels.
Real‑time RT‑PCR quantification for HIV‑RNA
Viral RNA was isolated from cell-culture supernatants 
using the QIAmp viral RNA mini kit (Qiagen) according 
to the manufacturer’s protocol. Collected RNA was treated 
with DNase, reverse transcribe and then amplified for 20 
cycles using primers specific for HIV-LTR (tagged with a 
lambda sequence) and HIV-GAG. The HIV-DNA was fur-
ther amplified using a lambda-specific primer and an inner 
HIV-LTR primer as well as two fluorescent probes specific 
for HIV-LTR, using a protocol adapted from [82].
Statistics
Statistical analyses were performed using the GraphPad 
Prism 5. Details are included in Figure legends.
Additional files
Additional file 1. Purity of flow cytometry‑sorted memory CD4+ T‑cell 
subsets. Total CD4+ T‑cells were isolated from PBMCs of healthy individu‑
als by negative selection using magnetic beads (Miltenyi). Cells were 
stained with a cocktail of fluorochrome‑conjugated Abs and analyzed by 
polychromatic flow cytometry (see Supplemental Experimental Procedure). 
Memory (CD45RA−) cells lacking the lineage‑specific markers CD8 (CD8+ 
T‑cells), CD19 (B cells), and CD56 (NK cells) and with differential expression 
of CCR6, CCR4, and CXCR3 were sorted by flow cytometry (BDAria II) as 
follows: CCR6+CCR4+CXCR3− (Th17), CCR6+CCR4−CXCR3− (CCR6+DN), 
CCR6+CCR4+CXCR3+ (CCR6+DP), CCR6+CCR4−CXCR3+ (Th1Th17) and 
CCR6−CCR4−CXCR3+ (Th1). A viability staining was used to exclude dead 
cells. The positivity gates where defined based on fluorescence minus one 
(FMO) controls. Shown is (A) the gating strategy for the identification of 
different subsets on CD4+ T‑cells sorted by MACS and (B) purity upon FACS 
sorting of different memory T‑cell subsets. The percentage of each subset 
is indicated on the figures. Results are from one donor representative of 
experiments performed with cells from >10 different donors. The positivity 
gates where defined based on fluorescence minus one (FMO) controls.
Additional file 2. Genome‑wide transcriptional profiling of the newly 
identified CCR6+DN and CCR6+DP subsets relative to the previously charac‑
terized Th17/CCR4+CCR6+ cells. See attached document.
Additional file 3. GO classification of differentially expressed genes 
in 3 CCR6+ subsets. (A-B) Shown are Venn diagram representation of 
GSVA‑generated canonical pathways (A) and biological functions (B), 
illustrating the number of differentially expressed pathways common or 
unique between Th17, CCR6+DN, and CCR6+DP. (C-F) Further, differentially 
expressed genes between (p < 0.05, FC cut‑off 1.3) were classified based 
on their biological functions using Gene Ontology (GO) as follows: (C) Cell 
migration (D) Chemotaxis (E) Cell differentiation, and (F) Transcription 
factors. The heatmaps were generated using the R programming language 
and the heatmap and ggplot2 libraries (R Core Team). For each heat map, 
genes up and down regulated in different subsets are represented in red 
and blue, respectively.
Additional file 4. Superior Th17‑lineage commitment of CM versus EM 
Th17 and Th1Th17‑subsets. FACS‑sorted Th17, Th1Th17 and Th1 subsets 
with CM (CD45RA−CCR7+) and EM (CD45RA−CCR7−) phenotype were cul‑
tured for 14 days under Th17‑polarizing conditions, as in Fig. 5. Shown are 
the statistical analyses of the intracellular expression of IL‑17A, IL‑17F, IL‑22, 
IFN‑γ and TNF‑α by distinct Th17‑polarized CM (black bars) versus EM (white 
bars) Th17, Th1Th17 and Th1 subsets. Results (mean ± SEM) were generated 
with matched samples from n = 3 different subjects. Paired t‑test p‑values 
are indicated in the figures (CM versus EM).
Additional file 5. Flow cytometry analysis of cytokine co‑expression at 
single‑cell level by CM subsets upon long‑term culture under Th17 versus 
Th1 polarizing conditions. Central memory (CM) Th17, Th1Th17, CCR6+DN, 
CCR6+DP, and Th1 subsets were sorted and cultured for 14 days under 
Th17 or Th1 polarizing conditions, as described in Fig. 5. Shown are flow 
cytometry dot plots illustrating the co‑expression of IL‑17A with IL‑17F, IL‑22, 
IFN‑γ or TNF‑α for each Th17‑ or Th1‑polarized subset. Results are from one 
donor representative of results generated with cells from three different 
donors. The positivity gates where defined based on fluorescence minus 
one (FMO) controls.
Additional file 6. Poly‑functional profiles of CM CCR6+ subsets upon 
long‑term culture under Th17 versus Th1 polarizing conditions in vitro. FACS‑
sorted CM subsets were analyzed for the expression of lineage‑specific 
cytokines upon Th17/Th1‑polarization in vitro (Fig. 5). Shown are bar graph 
representations generated with SPICE software for all possible combina‑
tions of one (blue), two (green), three (orange), four (yellow), and five (red) 
or no (purple) cytokines produced by T‑cell subsets upon culture in vitro 
(mean ± SEM), together with pie charts summarizing the polyfunctional 
profiles (median relative contribution, n = 3).
Additional file 7. Phenotypic stability versus plasticity of the four central 
memory CCR6+ T‑cell subsets under Th17‑ or Th1‑polarizing conditions. 
FACS‑sorted CM subsets were cultured under Th17‑ and Th1‑polarizing 
conditions for 14 days, as described in Fig. 5A, stained with CCR6, CCR4, and 
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